含遗传灭活百日咳毒素的重组百日咳加强疫苗在育龄女性中的2期随机对照剂量探索试验
在泰国育龄女性中开展2期随机对照试验,250人随机接受五种含不同剂量遗传灭活百日咳毒素(PTgen)或化学灭活百日咳类毒素(PTchem)的疫苗之一。所有疫苗均安全,PT-IgG血清应答率均达到预设的95%CI下限≥50%的免疫原性标准。
要点
- ap1gen组PT-IgG血清应答率92%(95%CI 81-98),Tdap1gen组88%(95%CI 76-95)。
- Tdap2gen组80%(95%CI 66-90),TdaP5gen组94%(95%CI 83-99),Tdap8chem组78%(95%CI 64-88)。
- 各组注射部位和全身反应频率相当,28天观察期内未报告严重不良事件。
核心结论
- 所有重组无细胞百日咳疫苗在育龄女性中安全且有免疫原性,均达到预设的免疫原性标准以推进至孕妇试验。
研究设计与样本
- 2期随机对照安全性及免疫原性试验,在泰国育龄女性中开展,共250人按1:1:1:1:1随机分组。
- 受试者接种单剂ap1gen、Tdap1gen、Tdap2gen、TdaP5gen或Tdap8chem疫苗之一。
- 接种前和接种后28天用ELISA检测血清IgG抗体。
主要发现
- 2018年7月5日至22日入组250名女性,中位年龄31岁。
- 接种后PT-IgG血清应答率:ap1gen组92%(95%CI 81-98),Tdap1gen组88%(95%CI 76-95),Tdap2gen组80%(95%CI 66-90),TdaP5gen组94%(95%CI 83-99),Tdap8chem组78%(95%CI 64-88)。
- 各组注射部位和全身反应频率相当。
- 接种后28天观察期内未报告严重不良事件。
关键数值与推荐
- 推进至孕妇试验的预设免疫原性标准为PT-IgG血清应答率的95%CI下限≥50%。
- ap1gen含1 μg PTgen和1 μg FHA;Tdap1gen为Td联合ap1gen;Tdap2gen为Td联合含2 μg PTgen和5 μg FHA的重组百日咳疫苗。
- TdaP5gen(Boostagen®)含5 μg PTgen和5 μg FHA;Tdap8chem(BoostrixTM)含8 μg化学灭活百日咳类毒素(PTchem)、8 μg FHA和2.5 μg百日咳黏附素(PRN)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin (PTgen) was conducted in women of childbearing age in Thailand to identify formulations to advance to a trial in pregnant women. METHODS: A total of 250 women were randomized 1:1:1:1:1 to receive one dose of one of three investigational vaccines including low-dose recombinant pertussis-only vaccine containing 1 μg PTgen and 1 μg FHA (ap1gen), tetanus, reduced-dose diphtheria (Td) combined to ap1gen (Tdap1gen) or combined to recombinant pertussis containing 2 μg PTgen and 5 μg FHA (Tdap2gen), or one dose of licensed recombinant TdaP vaccine containing 5 μg PTgen and 5 μg FHA (Boostagen®, TdaP5gen) or licensed Tdap vaccine containing 8 μg of chemically inactivated pertussis toxoid (PTchem), 8 μg FHA, and 2.5 μg pertactin (PRN) (BoostrixTM, Tdap8chem). Serum Immunoglobulin G (IgG) antibodies against vaccine antigens were measured before and 28 days after vaccination by ELISA. To advance to a trial in pregnant women, formulations had to induce a PT-IgG seroresponse rate with a 95% confidence interval (95% CI) lower limit of ≥ 50%. RESULTS: Between 5 and 22 July 2018, a total of 250 women with median age of 31 years were enrolled. Post-vaccination PT-IgG seroresponse rates were 92% (95% CI 81-98) for ap1gen, 88% (95% CI 76-95) for Tdap1gen, 80% (95% CI 66-90) for Tdap2gen, 94% (95% CI 83-99) for TdaP5gen, and 78% (95% CI 64-88) for Tdap8chem. Frequencies of injection site and systemic reactions were comparable between the groups. No serious adverse events were reported during the 28-day post-vaccination period. CONCLUSIONS: All recombinant acellular pertussis vaccines were safe and immunogenic in women of childbearing age, and all met pre-defined immunogenicity criteria to advance to a trial in pregnant women. CLINICAL TRIAL REGISTRATION: Thai Clinical Trial Registry, TCTR20180321004.
引用
- Chokephaibulkit K, Puthanakit T, Bhat N, et al. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age. Vaccine. 2021. PMID: 34789403. doi:10.1016/j.vaccine.2021.10.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。